This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma

This study has been withdrawn prior to enrollment.
(Study abandoned; Could not obtain final SRC approval due to IND disagreements)
Information provided by (Responsible Party):
Stanford University Identifier:
First received: March 4, 2010
Last updated: May 10, 2012
Last verified: May 2012
Phase II study of selective intra-arterial infusion of chemotherapy for intraocular retinoblastoma

Condition Intervention Phase
Retinoblastoma Eye Cancer Procedure: Intra-arterial infusion of chemotherapy Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Response: Globe salvage rate (Eyes saved/Eyes treated). This will be determined by clinical ocular examination. [ Time Frame: Follow-up will be performed for one year from treatment date. ]

Enrollment: 0
Study Start Date: September 2010
Estimated Study Completion Date: March 2012
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients diagnosed with advanced intraocular retinoblastoma (International Retinoblastoma Classification group D or E*).
  2. Patients with tumor recurrence or vitreous seeding following completion of systemic chemotherapy or previous radiation therapy.

Exclusion Criteria:

  1. Congenital brain anomaly identified on MRI.
  2. History of systemic coagulopathy.
  3. Evidence of extra ocular retinoblastoma on clinical examination or neuroimaging.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01151748

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Jonathan W Kim Stanford University
  More Information

Responsible Party: Stanford University Identifier: NCT01151748     History of Changes
Other Study ID Numbers: PEDSEYE0001
SU-07072009-3000 ( Other Identifier: Stanford University )
Study First Received: March 4, 2010
Last Updated: May 10, 2012

Additional relevant MeSH terms:
Eye Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Retinal Neoplasms
Neoplasms by Site
Eye Diseases
Retinal Diseases processed this record on August 18, 2017